← Leaderboards
Brian Barkley Graham
University Of Colorado Denver
$7,997,357
Attributed
$8,244,832
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2011–25$2M$1.5M$1M$500K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,244,832 · 7
By mechanism
R01$4,597,870 · 1
P01$2,343,225 · 2
K08$653,287 · 1
R21$464,950 · 1
R03$155,500 · 1
R13$30,000 · 1
Top collaborators
- Joan F Hilton2 shared
- Marjorie Patricia George1 shared
Most similar at University Of Colorado Denver
Same institution · by research overlap
- Raphael A. Nemenoff$15,000,654
- Kurt R Stenmark$22,132,904
- Rubin M Tuder$19,596,454
- Colleen Glyde Julian$3,623,041
- Mark Robert Nicolls$22,256,364
Others in their field
Top investigators on “Blood Vessels”
- Sonia M Thomas · Research Triangle Institute$353,402,726
- Tracy L Nolen · Research Triangle Institute$353,402,726
- Charles Decarli · University Of California At Davis$66,498,201
- Josef Coresh · New York University School Of Medicine$63,693,760
- Sterling C Johnson · St. Joseph'S Hospital And Medical Center$62,000,770
- Robert P Kimberly · University Of Alabama At Birmingham$56,093,149
Research focus
Blood VesselsPulmonary HypertensionLungPhenotypeSchistosomaSchistosomiasisPulmonary Arterial HypertensionInflammationPathogenesisCellsParasitesCytokineHypoxiaVascular RemodelingCd4 Positive T LymphocytesVascular DiseasesImmuneAdaptive ImmunityImmune SystemMonocytePreventTransforming Growth Factor BetaAffectNatural Immunity
Grant awards (31)
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$416,029
R01 · FY2025 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$93,032
R01 · FY2025 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$52,226
R01 · FY2025 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$45,681
R01 · FY2025 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$557,806
R01 · FY2024 · HL · contact PI
Role of Complement-Driven Pulmonary Vascular Inflammation in PH$478,800
P01 · FY2024 · HL · contact PI
Screening for schistosomiasis-associated pulmonary arterial hypertension$244,196
R21 · FY2024 · AI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$574,590
R01 · FY2023 · HL · contact PI
Role of Complement-Driven Pulmonary Vascular Inflammation in PH$488,572
P01 · FY2023 · HL · contact PI
Screening for schistosomiasis-associated pulmonary arterial hypertension$220,754
R21 · FY2023 · AI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$82,520
R01 · FY2023 · HL · contact PI
Determining the location and phenotype requirement of CD4 T cells in schistosomiasis pulmonary hypertension$54,862
R01 · FY2023 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$641,065
R01 · FY2022 · HL · contact PI
Role of Complement-Driven Pulmonary Vascular Inflammation in PH$488,572
P01 · FY2022 · HL · contact PI
Role of Complement-Driven Pulmonary Vascular Inflammation in PH$488,572
P01 · FY2021 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$403,750
R01 · FY2021 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$402,708
R01 · FY2020 · HL · contact PI
Role of Complement-Driven Pulmonary Vascular Inflammation in PH$398,709
P01 · FY2020 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$388,750
R01 · FY2019 · HL · contact PI
Investigating paclitaxel treatment in a pre-clinical model of Schistosoma-pulmonary hypertension$33,700
R01 · FY2019 · HL · contact PI
2019 Aspen Lung Conference: Exploring new therapeutic pathways in pulmonary hypertension: metabolism, proliferation, and personalized medicine$30,000
R13 · FY2019 · HL
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$436,296
R01 · FY2018 · HL · contact PI
Activation, Phenotype and Function of CD4 T Cells in Schistosoma-Pulmonary Hypertension$388,750
R01 · FY2017 · HL · contact PI
Role of Th2 CD4 T Cells in Schistosoma Pulmonary Hypertension$77,750
R03 · FY2017 · HL · contact PI
Investigating paclitaxel treatment in a pre-clinical model of Schistosoma-pulmonary hypertension$26,105
R01 · FY2017 · HL · contact PI
Role of Th2 CD4 T Cells in Schistosoma Pulmonary Hypertension$77,750
R03 · FY2016 · HL · contact PI
Schistosomiasis Associated Pulmonary Arterial Hypertension$130,624
K08 · FY2015 · HL · contact PI
Schistosomiasis Associated Pulmonary Arterial Hypertension$130,641
K08 · FY2014 · HL · contact PI
Schistosomiasis Associated Pulmonary Arterial Hypertension$130,658
K08 · FY2013 · HL · contact PI
Schistosomiasis Associated Pulmonary Arterial Hypertension$130,674
K08 · FY2012 · HL · contact PI
Schistosomiasis Associated Pulmonary Arterial Hypertension$130,690
K08 · FY2011 · HL · contact PI